Research programme: VCAM/VLA-4 inhibitors - Kaken

Drug Profile

Research programme: VCAM/VLA-4 inhibitors - Kaken

Alternative Names: Cell adhesion inhibitors research programme - Kaken; Research programme: cell adhesion inhibitors - Kaken; VCAM/VLA-4 antagonists research programme - Kaken

Latest Information Update: 24 Feb 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kaken Pharmaceutical
  • Class
  • Mechanism of Action Integrin alpha4beta1 antagonists; Vascular cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Inflammation

Most Recent Events

  • 02 Sep 2004 This programme is still in active development
  • 28 May 2001 Preclinical development for Asthma in Japan (Unknown route)
  • 28 May 2001 Preclinical development for Inflammation in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top